Search

Displaying results 4691 - 4700 of 9132 in total
  1. Drug

    PA-1050040

    go.drugbank.com/drugs/DB06039
    Experimental

    PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.

  2. Drug

    Cryptenamine

    go.drugbank.com/drugs/DB00785
    Approved

    Cryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). … Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.

  3. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.

  4. Drug

    C31G

    go.drugbank.com/drugs/DB05398
    Investigational

    in a phase III pivotal clinical trial for the reduction of sexual transmission of human immunodeficiency virus (HIV). … C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment

  5. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  6. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    in a lower risk of off-target effects, including hepatotoxicity. … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results

  7. Drug

    G17DT Immunogen

    go.drugbank.com/drugs/DB04914
    Investigational

    G17DT Immunogen is a vaccine that neutralizes gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. … It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine.

    Synonyms: G17DT (AN ANTIGASTRIN IMMUNOGEN)
  8. Drug

    Ormeloxifene

    go.drugbank.com/drugs/DB13310
    Experimental

    In India, ormeloxifene has been marketed since the 1990s as a non-hormonal, non-steroidal oral contraceptive taken once a week,[A251450] and it was later introduced for the treatment of dysfunctional uterine … [A251450,A251460] Ormeloxifene is marketed in India as a racemic mixture of the l- (levormeloxifene) and d-isomers (d-ormeloxifene) of _trans_-ormeloxifene.

  9. Drug

    Brodalumab

    go.drugbank.com/drugs/DB11776
    ApprovedInvestigational

    Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

    Categories: Interleukin-17 Receptor A Antagonist, Interleukin 17 Receptor A Antagonists
  10. Drug

    Diiodohydroxyquinoline

    go.drugbank.com/drugs/DB09115
    Approved

    Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown.

    Mixtures: Alcortin A, Alcortin A